港股异动 | 腾盛博药-B(02137)再涨超8% 近期向健康元集团授予新药BRII-693大中华区独家许可

智通财经2025-07-17

智通财经APP获悉，腾盛博药-B(02137)再涨超8%，截至发稿，涨8.21%，报2.11港元，成交额1167.83万港元。消息面上，腾盛博药此前宣布，旗下全资子公司腾盛博药美国与健康元集团签订知识产权许可及技术转移协议，授予健康元集团在中国大陆、香港、澳门和台湾等大中华地区，研究、开发和商业化新药BRII-693的独占许可。根据协议，健康元将全面负责BRII-693在大中华区的开发、监管审批和...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552172451?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-17 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552172451","market":"fut","top_or_hot":-1,"title":"港股异动 | 腾盛博药-B(02137)再涨超8% 近期向健康元集团授予新药BRII-693大中华区独家许可","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，腾盛博药-B(02137)再涨超8%，截至发稿，涨8.21%，报2.11港元，成交额1167.83万港元。消息面上，腾盛博药此前宣布，旗下全资子公司腾盛博药美国与健康元集团签订知识产权许可及技术转移协议，授予健康元集团在中国大陆、香港、澳门和台湾等大中华地区，研究、开发和商业化新药BRII-693的独占许可。根据协议，健康元将全面负责BRII-693在大中华区的开发、监管审批和...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1318824.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 腾盛博药-B(02137)再涨超8% 近期向健康元集团授予新药BRII-693大中华区独家许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 腾盛博药-B(02137)再涨超8% 近期向健康元集团授予新药BRII-693大中华区独家许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-17 10:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1318824.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，腾盛博药-B(02137)再涨超8%，截至发稿，涨8.21%，报2.11港元，成交额1167.83万港元。消息面上，腾盛博药此前宣布，旗下全资子公司腾盛博药美国与健康元集团签订知识产权许可及技术转移协议，授予健康元集团在中国大陆、香港、澳门和台湾等大中华地区，研究、开发和商业化新药BRII-693的独占许可。根据协议，健康元将全面负责BRII-693在大中华区的开发、监管审批和...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1318824.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1318824.html","article_id":"2552172451","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552172451","pubTimestamp":1752720051,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，腾盛博药此前宣布，旗下全资子公司腾盛博药美国与健康元集团签订知识产权许可及技术转移协议，授予健康元集团在中国大陆、香港、澳门和台湾等大中华地区，研究、开发和商业化新药BRII-693的独占许可。根据协议，健康元将全面负责BRII-693在大中华区的开发、监管审批和商业化。腾盛博药美国已收取首付款，未来在达成相关里程碑事件时，将收到额外的开发和商业化里程碑付款，并将根据BRII-693的产品净销售额按约定比例获得销售分成。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600380":"健康元","BK1587":"次新股","BK0188":"融资融券","BK1161":"生物科技","BK0114":"健康中国","BK1574":"生物医药B类股","02137":"腾盛博药-B","BK0077":"质押式回购","BK0046":"生物疫苗","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"Changes in Hong Kong stocks | Tengsheng Boyao-B (02137) rose more than 8% and recently granted the exclusive license for the new drug BRII-693 Greater China to Joincare Group","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600380":1,"02137":1},"content_text":"智通财经APP获悉，腾盛博药-B(02137)再涨超8%，截至发稿，涨8.21%，报2.11港元，成交额1167.83万港元。消息面上，腾盛博药此前宣布，旗下全资子公司腾盛博药美国与健康元集团签订知识产权许可及技术转移协议，授予健康元集团在中国大陆、香港、澳门和台湾等大中华地区，研究、开发和商业化新药BRII-693的独占许可。根据协议，健康元将全面负责BRII-693在大中华区的开发、监管审批和商业化。腾盛博药美国已收取首付款，未来在达成相关里程碑事件时，将收到额外的开发和商业化里程碑付款，并将根据BRII-693的产品净销售额按约定比例获得销售分成。公告称，BRII-693是一种在研新型合成脂肽，用于治疗多重耐药和广泛耐药(MDR/XDR)革兰氏阴性菌感染的重症患者。腾盛博药已从国家药监局药品审评中心取得临床试验许可，获准在中国开展BRII-693的一期药代动力学桥接研究，以支持未来在医院获得性细菌性肺炎/呼吸机相关细菌性肺炎患者中开展三期注册性试验。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552172451","isCrawlerRequest":true}